文献速递心血管MR

三磷酸腺苷(ATP)作为负荷灌注心脏磁共振血管扩张剂的安全性与有效性

Adenosine triphosphate (ATP): a safe and effective vasodilator for stress perfusion cardiac magnetic resonance imaging.
PubMed 文献 · Clin Radiol · 2022-11-06

本研究回顾性纳入107例使用ATP进行负荷灌注心脏磁共振(CMRI)的患者,评估其安全性和有效性。结果显示ATP血流动力学反应快速,2分钟内见效,35%患者出现轻微不良事件,无心肌梗死或支气管痉挛,91%患者出现脾脏开关效应(SSO)作为充分负荷的指标。结论认为ATP作为冠状动脉血管扩张剂是安全的,SSO可作为ATP负荷CMRI负荷成功的指标。

要点

  • ATP负荷CMRI中SSO现象出现率91%,可作为负荷成功的影像指标。
  • ATP输注期间不良事件多为轻度(35%),2分钟内缓解,无严重并发症。
  • 3例因房室传导阻滞终止扫描,需注意心电图监测。

关键影像表现/征象

  • SSO现象(脾脏信号减低)在91%(94/103)的患者中观察到,作为充分负荷的标记。
  • ATP输注后2分钟内出现血流动力学反应(心率增加≥10次/分)。
  • 3例患者因房室传导阻滞终止扫描,7例图像质量不佳被排除分析。

诊断标准与关键数值

  • 血流动力学反应定义为心率增加≥10次/分,2分钟内出现。
  • SSO现象出现率91%(94/103)作为负荷成功的指标。
  • 不良事件发生率35%(37/107),均为轻度,包括胸痛、潮红、呼吸困难、头痛和房室传导阻滞。

临床应用与阅片要点

  • ATP负荷CMRI时观察SSO现象可快速判断负荷是否充分。
  • 输注ATP期间需监测心电图,警惕房室传导阻滞,备好终止准备。
  • 轻度不良事件多在停药2分钟内缓解,无需特殊处理。

局限性

  • 回顾性单中心设计,样本量有限(107例)。
  • 7例图像质量不佳被排除,可能引入选择偏倚。
  • 未报告敏感度、特异度等诊断准确性指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To evaluate the efficiency and safety of adenosine triphosphate (ATP) as a stress agent in a cohort of patients undergoing stress perfusion cardiac magnetic resonance imaging (CMRI).

MATERIALS AND METHODS: This retrospective study was conducted between December 2019 and October 2021. The study recruited patients who underwent stress perfusion CMRI using ATP as a vasodilator. Adverse events, such as chest pain, flushing, dyspnoea, headache, and splenic switch-off (SSO) phenomenon, were evaluated in the patients who underwent stress perfusion CMRI.

RESULTS: The study included 107 patients (age range: 53 ± 11 years; male:female, 62%:38%). The haemodynamic response (heart rate increased by ≥ 10 beats/min) was quick and observed within 2 minutes of ATP infusion. Scanning was stopped in three patients because of atrioventricular block. CMRI images of seven out of 104 patients were excluded from the final analysis because of inferior quality. During ATP infusion, 37/107 patients (35%) experienced mild adverse events, such as chest pain, flushing, dyspnoea, headache, and atrioventricular block. Myocardial infarction and bronchospasms were not observed during ATP infusion. SSO, a marker of adequate stress, was observed in 91% (94/103) of the patients who underwent stress perfusion CMRI.

CONCLUSIONS: As a coronary vasodilator, ATP was safe for stress perfusion CMRI. In addition, the adverse events during ATP infusion were mild, which were relieved within 2 minutes of ATP injection cessation. SSO could serve as an indicator of stress success in ATP stress perfusion CMRI.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Kong, An, Cao, et al. Adenosine triphosphate (ATP): a safe and effective vasodilator for stress perfusion cardiac magnetic resonance imaging. Clin Radiol. 2022. PMID: 36351853. doi:10.1016/j.crad.2022.08.133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。